All In Biotech

Free tool

FAERS Monitor: Intrarosa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208470 or its brand name (Intrarosa, Prasterone). Reports on generic versions are filed under their own applications.

Reports

2,752

Serious

892

32% of reports

Hospitalization

294

Death reported

47

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use803
  • fatigue171
  • headache171
  • drug ineffective168
  • nausea132
  • product dose omission issue130
  • application site discharge115
  • rash95
  • dizziness94
  • insomnia93
  • pain92
  • vaginal discharge85
  • alopecia81
  • pruritus81
  • vulvovaginal burning sensation80

Reports by year received

View as table
YearReports
20048
20054
20084
20092
201011
201135
201258
20133
20146
201510
201619
201724
2018312
2019441
2020301
2021209
2022258
2023300
2024228
2025291
2026228

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,407 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site dischargeSignal115846.7700.986,702
vulvovaginal burning sensationSignal80101.581.77,759
vaginal dischargeSignal8564.752.45,227
off label useSignal8037.06.64,311
product dose omission issueSignal1303.42.9218
alopeciaSignal813.22.5118
insomniaSignal932.72.297
headacheSignal1712.11.898
fatigue1711.71.548
rash951.71.425
pruritus811.61.318
dizziness941.41.213
nausea1321.31.18
pain921.10.92
drug ineffective1681.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.